高级检索
    夏忠军, 李文瑜. 无论诱导阶段是否曾使用过利妥昔单抗维持治疗均可改善复发/难治滤泡性淋巴瘤临床预后Ⅲ期随机对照研究的评价[J]. 循证医学, 2007, 7(1): 20-22. DOI: 10.3969/j.issn.1671-5144.2007.01.008
    引用本文: 夏忠军, 李文瑜. 无论诱导阶段是否曾使用过利妥昔单抗维持治疗均可改善复发/难治滤泡性淋巴瘤临床预后Ⅲ期随机对照研究的评价[J]. 循证医学, 2007, 7(1): 20-22. DOI: 10.3969/j.issn.1671-5144.2007.01.008
    shu
    XIA Zhong-jun, LI Wen-yu. Evaluation of the Rituximab Maintenance Improves Clinical Outcome of Relapsed/Resistant Follicular Non Hodgkin's Lymphoma, Both in Patients with and without Rituximab during Induction: Results of A Prospective Randomized Phase Ⅲ Intergroup Trial[J]. Journal of Evidence-Based Medicine, 2007, 7(1): 20-22. DOI: 10.3969/j.issn.1671-5144.2007.01.008
    Citation: XIA Zhong-jun, LI Wen-yu. Evaluation of the Rituximab Maintenance Improves Clinical Outcome of Relapsed/Resistant Follicular Non Hodgkin's Lymphoma, Both in Patients with and without Rituximab during Induction: Results of A Prospective Randomized Phase Ⅲ Intergroup Trial[J]. Journal of Evidence-Based Medicine, 2007, 7(1): 20-22. DOI: 10.3969/j.issn.1671-5144.2007.01.008
    shu

    无论诱导阶段是否曾使用过利妥昔单抗维持治疗均可改善复发/难治滤泡性淋巴瘤临床预后Ⅲ期随机对照研究的评价

    Evaluation of the Rituximab Maintenance Improves Clinical Outcome of Relapsed/Resistant Follicular Non Hodgkin's Lymphoma, Both in Patients with and without Rituximab during Induction: Results of A Prospective Randomized Phase Ⅲ Intergroup Trial

      摘要
      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回